Multiple Sclerosis, Relapsing-Remitting

- Provides written informed consent to participate in the study
- At least 18 but no more than 65 years old
- Documented clinical diagnosis of a relapsing form of multiple sclerosis or confirmed clinically isolated syndrome (CIS)
- Initiating Betaseron therapy, or resuming Betaseron after not having used it for at least three months
- Willing and able to provide a valid e-mail address which will be in use for the duration of the study
- Willing and able to complete study questionnaires via the Internet
- Has reliable Internet access for the duration of the study
- Completes the baseline patient questionnaire

- Kurtzke Expanded Disability Status Scale (EDSS) score greater than 6.0
- Cognitive dysfunction that, in the Investigator’s judgment, raises doubts about the study participant’s ability to provide informed consent or accurately complete the monthly patient questionnaire
- Any use of Betaseron within the three months prior to study entry
- Inability to read, write, or speak the English language
- Illness or disease other than multiple sclerosis that the Investigator believes is likely to cause the patient’s death or incapacity within twelve months
- Any severe, uncontrolled illness or condition that the Investigator believes could dominate the patient’s quality of life
- Coexistent autoimmune disease such as rheumatoid arthritis, lupus, or psoriasis that is likely to be exacerbated by treatment with Interferon
- Current use of any immunosuppressive medication
- Previous participation in a multiple sclerosis (MS) clinical trial within the three months prior to study entry
- Previous use of monoclonal antibodies treating MS within the three months prior to study entry
- Current use of any secondary treatment for multiple sclerosis other than the episodic use of steroids during relapses or exacerbations